Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-04-24
2007-04-24
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S256000
Reexamination Certificate
active
10679209
ABSTRACT:
Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases , inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.
REFERENCES:
patent: 2667486 (1954-01-01), Cain
patent: 5214059 (1993-05-01), Tegeler et al.
patent: 5597901 (1997-01-01), Stern
patent: 5776502 (1998-07-01), Foulkes et al.
patent: 5830880 (1998-11-01), Sedlacek et al.
patent: 6070126 (2000-05-01), Kokolus et al.
patent: 6121434 (2000-09-01), Peyman
patent: 6136779 (2000-10-01), Foulkes et al.
patent: 6194191 (2001-02-01), Zhnag et al.
patent: 6204260 (2001-03-01), Bruns, Jr. et al.
patent: 6326487 (2001-12-01), Peyman et al.
patent: 6348312 (2002-02-01), Peyman et al.
patent: 6471968 (2002-10-01), Baker, Jr. et al.
patent: 6489328 (2002-12-01), Snow et al.
patent: 6506769 (2003-01-01), Snow et al.
patent: 6635626 (2003-10-01), Barrish et al.
patent: 6685938 (2004-02-01), Cheresh et al.
patent: 6689778 (2004-02-01), Benis et al.
patent: WO 2004/005283 (2004-01-01), None
patent: WO 02/097116 (2002-12-01), None
patent: WO 2004/032709 (2004-04-01), None
patent: WO 2004/037814 (2004-05-01), None
S. Taghavi-Moghadam and W. Pfleiderer, “A New, General and Regioselective Method for the Synthesis of 2,6-Disubsituted 4-Aminopteridines”,Elsevier Science Ltd., Pergamon, 6835-6836, 1997.
Lothar G. Fröhlich et al., “Inhibition of Neuronal Nitric Oxide Synthase by 4-Amino Pteridine Derivatives: Structures-Activity Relationship of Antagonists of (6R)-5,6,7,8-Tetrahydrobiopterin Cofactor”,J. Med. Chem., vol. 42, 4108-4121, 1999.
T. Weber, Ph.D., “Molecular Approaches to Study Cellular Roadblocks to Transfection and Transduction (Non-Viral Vectors and AAV-Based Vectors for Gene Therapy)”, http://www.mssm.edu/genetherapy/weber.htm, 1-8, Nov. 11, 2002.
N. Kobayashi et al., “Functional coupling of the src-family protein tyrosine kinases p59fyn and p53/56lyn with the interleukin 2 receptor: implications for redundancy and pleiotropsim in cytokine signal transduction”,Proc. Natl. Acad. Sci., USA, vol. 1:90, No. 9, 4201-4205, Abstract, PMID 8483935, May 1993.
New Mexico Department of Health, INTERLEUKIN-2, http://www.aidsinfonet.org,Project of the New Mexico Aids Education and Training Center, Fact Sheet No. 622, Apr. 30, 2002.
N. Tanaka et al., “novel human tyrosine kinase gene inducible in T cells by interleukin 2”,FEBS Lett., vol. 7:324, No. 1, 1-5, PMID 9504851, Jun. 1993.
A. Granelli-Piperno, “SRC-related proto-oncongenes and transcription factors in primary human T cells: modulation by cyclosporine A and FK506”,J. Autoimmun., vol. 5, Suppl. A, 145-158, PMID 1380242, Apr. 1992.
T. Torigoe et al., “Regulation of SRC-family protein tyrosine kinases by interleukin, IL-2, and IL-3”,Leukemia, vol. 6, Supplemental 3, 94S—97S, PMID 1602836, 1992.
J.J. O'Shea et al., “Expression of v-src in a murine T-cell hybridoma results in constitutive T-cell receptor phosphorylation and interleukin 2 production”,Proc. Natl. Acad. Sci. USA, vol. 1;88, No. 5, 1741-1745, PMID 200381, 1991.
J.B. Bolen et al., “Expression and interaction of the Src family of tyrosine protein kinases in T lymphocytes”,Adv. Cancer Res., vol. 57., 103-149, PMID 1950702, 1991.
T. Yamamoto et al., “Role of src-like protooncogenes in lymphocotye proliferation”,Princess Takamastu Symp., vol. 22, 293-305 Review, PMID 1668889, 1991.
Dneprovskaia Elena
Doukas John
Gong Xianchang
Hood John D.
Noronha Glenn
Saeed Kamal A.
TargeGen, Inc.
LandOfFree
Vasculostatic agents and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vasculostatic agents and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vasculostatic agents and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3735971